韩国制药、生物科技等企业素有向资深员工发放黄金作为工龄奖励的传统，但受近两年国际金价飙升影 响，多家药企难以承担财务压力，改为向员工发放现金。 来源：新华社 这种奖励变化源于国际及韩国国内金价飙升。国际现货黄金价格、纽约商品交易所4月黄金期货价格28 日均突破每盎司5500美元历史新高。国际金价从每盎司4000美元涨到5500美元，仅经过不到三个月时 间。而2024年初，国际金价只是略高于2000美元。 据《韩国商业电讯》29日报道，韩国知名生物制药企业GC控股公司以往会向为公司供职满10年、20 年、30年和40年的老员工，对应发放重量为10钱、20钱、30钱和40钱的黄金作为奖励。"钱"是韩国金价 传统计算单位，1钱折合3.75克。 据《韩国时报》报道，本月，韩国每钱黄金购买价突破100万韩元这一关键关口，较2025年初几乎翻了 一番，当时为每钱53.3万韩元。叠加韩元贬值影响，韩国国内黄金采购成本进一步提高，企业发放黄金 奖励的财务负担持续加剧。 但从今年开始，该公司改为向符合上述工龄的员工分别发放500万韩元（100万韩元约合4830元人民 币）、1000万韩元、1500万韩元和2000万韩元的现金奖 ...

Group 1 - SpyGlass Pharma, a biotechnology company focused on chronic eye disease treatments, is in the third phase of clinical trials and has announced its IPO terms, planning to issue 9.4 million shares at a price range of $15-17 per share, aiming to raise $150 million [1] - The fully diluted market capitalization of SpyGlass Pharma is projected to reach $549 million based on the midpoint of the proposed price range [1] - The company's core product is the Bimatoprost Implantable Lens System (BIM-IOL), designed to lower elevated intraocular pressure in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) during routine cataract surgery [1] Group 2 - SpyGlass Pharma was founded in 2019 and plans to list on NASDAQ under the ticker symbol "SGP" [2] - The underwriters for the IPO include Jefferies, Leerink Partners, Citigroup, and Stifel [2]

在这个充满"黑天鹅"与"灰犀牛"的时代，我们的情绪很容易被短期的市场波动和地缘政治的噪音所裹挟。 当移动互联网的红利逐渐见顶，AI的算力竞赛进入白热化，资本市场正在焦急地寻找下一个能够承载万亿市值 的"长坡厚雪"。 《钱伯斯词典》对这个术语给出了较为详尽的定义： 依托有机生物体（如细菌）或其酶系，在工业领域生产实用品，或开发应用于能源生产、废物处理、药物与激素 制造等多领域的工艺技术。 由此可见，生物科技的内涵远不限于医疗保健领域。尽管多数人在听到这个词时，往往首先联想到药物疗法的研 发，这无疑是该行业的一个重点，但本书采用的定义更加宽泛，涵盖了更根本且更具普遍意义的主题。 利用生物系统和有机体创造对人类有益的产品，早已超越了单纯的治愈疾病范畴。几千年来人类一直这么做，而 如今，得益于诸多振奋人心的结构性变革，我们正处在一场颠覆性技术飞跃的起点。生物科技及相关产业的蓬勃 发展，将对人类生活产生巨大影响，从农业生产、清洁能源的产生，到更强大的计算机的开发，都将受益其中。 毫不夸张地说，生物科技对于解决全球粮食问题至关重要，不仅能维系发达国家现有的生活方式，还能惠及发展 中国家，使其能享受同等质量的生活水平。尤为 ...

Core Viewpoint - South Korean pharmaceutical and biotech companies are shifting from providing gold as a long-standing service award to cash payments due to the financial pressure caused by soaring international gold prices [1] Group 1: Industry Changes - The tradition of awarding gold to senior employees is being replaced by cash payments as companies face increased financial burdens [1] - The international spot gold price and New York Mercantile Exchange April gold futures both surpassed $5,500 per ounce, marking a historical high [1] Group 2: Price Trends - The price of international gold rose from $4,000 to $5,500 per ounce in less than three months [1] - At the beginning of 2024, the international gold price was just above $2,000 per ounce [1]

● 本报记者 王鹤静 作为银行系公募基金的代表机构，近年来兴业基金在巩固固收投资优势的基础上，以指数投资为切入 口，大力推动权益投资发展。近日，兴业基金推出公司旗下首只QDII公募基金——兴业恒生科技指数 （QDII），为投资者提供一键参与港股科技板块的投资利器。 日前，兴业基金指数投资团队负责人、兴业恒生科技指数（QDII）拟任基金经理徐成城在接受中国证 券报记者采访时表示，站在当前的市场位置，港股科技类资产凭借其稀缺性以及相对较低的估值，对于 海内外资金而言，均有显著的配置价值。而且，通过QDII的形式还能够参与港股通以外的优质标的配 置机会，助力投资者充分享受科技浪潮下的投资机遇。 稀缺性与低估值优势凸显 作为公司旗下首只QDII产品，兴业基金首先选择试水的是跟踪恒生科技指数的场外产品。徐成城表 示，这样的选择是基于市场判断、资金观察、产品布局、自身能力等多方因素综合考虑的结果。 "从市场环境来看，新质生产力承担起我国提升生产效率的重任，围绕这类资产展开的投资策略有助于 帮助投资者实现资产的保值增值。由于成长类资产整体估值偏贵，而且产业发展存在不确定性，作为专 业投资者，我们需要帮助大家寻找其中具备相对 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603077 证券简称：和邦生物 公告编号：2026-007 债券代码：113691 债券简称：和邦转债 四川和邦生物科技股份有限公司 关于集中竞价减持公司已回购股份计划的公告 注：由于公司"和邦转债"已进入转股期，公告中涉及的比例计算以公司截至2026年1月28日总股本即 8,831,537,228股为基数计算。 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 回购股份的基本情况 为维护公司价值及股东权益，四川和邦生物科技股份有限公司（以下简称"公司"）于2024年4月至6月、 2024年6月至8月期间，通过集中竞价交易方式回购公司股份合计227,027,340股，占公司总股本的 2.57%。根据公司前期披露的相关回购股份方案，前述回购的股份将在披露回购结果暨股份变动公告12 个月后采用集中竞价交易方式出售，公司如未能在披露回购结果暨股份变动公告之后3年内实施前述用 途，尚未使用的部分将予以注销。具体内容详见公司在上海证券交易所网站（w ...

赵燕表示："我觉得作为我们企业来说，最大的收获就是从单点能力的积蓄到了系统性能力的沉淀成 型，尤其是我们打通了生命健康、情绪价值和城市生活方式的融合。" "我们是全球第一个将一个生物科技公司的科技生命消费品的品牌去冠名了两地。"赵燕指出，将生命科 技和我们的现代生活方式、情绪价值结合在一起的目的都是为了大家来打造一种新的一种生活方式，使 大家不要认为科技都是高高在上的，它是走进了我们的生活，就在我们的身边，实际上是时时刻刻在关 注着大家。我觉得我们做事的最终的目标都是为了让人能够有质量的活得长，要健康美丽才能快乐。这 是我觉得2025年对我们来说是最重要的一年。真正的打通了从科技然后走向生活，让大众能够在身边能 感知得到。 专题：为中国经济点赞——企业家之夜2025盛典 "为中国经济点赞——企业家之夜"于1月29日在北京举行。回忆2025，展望2026，华熙国际投资集团有 限公司董事长、华熙生物科技股份有限公司董事长兼总裁赵燕指出，2025年是一个充满挑战但是也蛮有 收获的一年。 新浪声明：所有会议实录均为现场速记整理，未经演讲者审阅，新浪网登载此文出于传递更多信息之目 的，并不意味着赞同其观点或证实其描述。 ...

Core Viewpoint - The "14th Five-Year Plan" period has seen significant advancements in Hubei's development, marked by six visible transformations that enhance both industrial capabilities and the quality of life for residents [1][2]. Group 1: Economic Development - Hubei has experienced a leap in development capabilities, with a focus on technological innovation and industrial upgrades, particularly in the automotive sector, where logistics times for exports have been reduced from 45 days to 18 days [2]. - The Huanggang High-tech Zone has entered the top 100 national high-tech zones, with 150 industrial enterprises and 253 national high-tech enterprises now established [2][3]. Group 2: Ecological and Social Improvements - There has been a notable enhancement in ecological quality and public welfare, with policies in education, healthcare, and talent attraction contributing to a better living environment for entrepreneurs [2]. - The commitment to ecological protection and sustainable development is evident, with initiatives aimed at creating a biodiversity protection demonstration area and promoting green tourism [5]. Group 3: Strategic Initiatives - The "Five Major Adherences" action path has been established to prioritize ecological protection, tourism, green development, and community welfare, aiming to create a model for sustainable living [5][6]. - The focus on high-quality development and strategic positioning as a key hub in central China is emphasized, with plans for infrastructure improvements and the introduction of new industries [8].

Group 1 - Hong Kong's capital market is projected to regain the top position in global IPO fundraising in 2025, with a total of $37.4 billion, surpassing the total of the previous three years and marking the highest level since 2021 [1] - The strong performance is driven by eight IPOs exceeding $1 billion and a diverse range of new economy companies, indicating a shift towards a more diversified market structure [1] - Newly listed stocks have shown positive performance, with an average first-day increase of 23.8% and a cumulative first-month increase of 30.7%, particularly in the biotechnology and healthcare sectors [1] Group 2 - The A+H share listing has emerged as a significant highlight, with 19 A-share companies completing H-share listings in 2025, raising $17.7 billion and enhancing the international investor base for these companies [2] - By the end of 2025, 96 A-share companies had submitted applications for listing in Hong Kong, with over 70 expressing intent to list, suggesting that A+H listings may continue to be a focus in 2026 [2] - The derivatives market is expanding alongside new stock listings, with the introduction of stock options for companies like CATL, providing investors with immediate risk management tools [2]

Core Viewpoint - PAG has achieved significant returns from its investment in Boryu Biotech, marking a successful exit in the Chinese private equity market with a transaction valued at approximately $6.8 billion, the largest of its kind in history [5][6][19]. Investment Performance - PAG's investment in Boryu Biotech has yielded around 3 billion yuan in returns over approximately 39 months, with the firm holding a 44.62% stake valued at over 6 billion yuan prior to the company's IPO [6][21][22]. - The investment strategy included acquiring shares from the parent company, Haizheng Pharmaceutical, and additional funding rounds, leading to a total investment exceeding 4.1 billion yuan [10][19]. Company Growth and Development - Boryu Biotech was established as a strategic response to Haizheng Pharmaceutical's restructuring efforts in 2019, focusing on monoclonal antibody drugs and securing PAG as a key investor [10][11]. - The company has rapidly expanded its product pipeline in immunotherapy, achieving over 1 billion yuan in profit within nine months and projecting revenues to grow from approximately 1.257 billion yuan in 2023 to 1.623 billion yuan in 2024 [13][16]. Market Position and Future Prospects - Boryu Biotech has established itself as a leading player in the immunotherapy sector, with a strong sales and marketing team covering over 4,000 hospitals and 2,000 retail pharmacies in China [15]. - The company has a robust patent portfolio with 43 granted patents and 63 pending applications, enhancing its competitive edge in the market [15]. - Following its IPO, Boryu Biotech is expected to raise additional funds for operations and product development, further solidifying its market position [16][23].